Blackrock Neurotech is a biomedical technology company specializing in brain-computer interface (BCI) systems, primarily developing implantable electrodes, hardware, and software to record and translate neural signals into actions for people with paralysis and neurological disorders.[1][2][4] Its flagship product, the Utah Array (also known as the NeuroPort Electrode), is the world's most advanced and longest-lasting intracortical electrode, used in nearly all human BCI implants since 2004, enabling applications like neuroprosthetics, computer control, communication, and sensory restoration.[1][5] The company serves over 1,000 research labs worldwide and patients through clinical trials, with its MoveAgain medical device receiving FDA Breakthrough Designation in 2021; it has powered over 2,000 published studies and 30,000+ collective implant days.[1][2][3]
Blackrock Neurotech traces its roots to Bionic Technologies, a 1997 spin-off from the University of Utah, which pioneered high-tech innovations including the Utah Array—a 10x10 platinum and silicon electrode grid for penetrating the cortex to record single neurons.[4][7] The company, originally Blackrock Microsystems, was formally founded in 2008 (active since then), with key involvement from figures like Brian Hatt and Prof. (not fully named in sources); it acquired Cyberkinetics, incorporating the Utah Array and other University of Utah-developed interfaces.[4][7] Pivotal early moments include the 2004 implantation of the Utah Array in Matt Nagle as part of BrainGate trials, allowing him to control an artificial hand by thought, marking the first human BCI use; subsequent milestones involved wireless transmitters, word decoding from thought (93% accuracy on 50 words), and at-home portable systems.[7]
Blackrock Neurotech rides the surging BCI trend, fueled by advances in neural engineering to restore function for paralysis, epilepsy, and neurodegenerative diseases amid an aging population and rising neurological disorder prevalence.[1][5][8] Its timing aligns with FDA Breakthrough Designations and clinical trials (30+ Cortivis implants by 2023 for robot control), positioning it as the backbone of foundational BCI research since 2004, influencing ecosystems from university labs (e.g., BrainGate, UCSF, Pitt) to medtech commercialization.[4][7] Market forces like growing demand for neuroprosthetics and wireless systems favor its 20-year track record, enabling broader adoption in research (2K+ studies) and potential consumer applications like thought-controlled interfaces.[2][9]
Blackrock Neurotech is poised to lead BCI commercialization with MoveAgain's FDA pathway and expansions in portable, at-home systems for neuroprosthetics and sensory restoration.[1][7] Trends like high-density neural decoding, AI integration for speech/motor recovery, and visual prosthetics will accelerate its growth, potentially expanding from 1,000+ research customers to widespread clinical use amid rising medtech investments.[2][8] Its influence may evolve from research enabler to mainstream life-changer for paralysis patients, transforming thought into action as the most proven BCI platform.[1][4]
